首页> 外文OA文献 >Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children.
【2h】

Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children.

机译:肾病儿童尿液中淋巴因子可溶性免疫反应抑制剂的鉴定。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients with minimal change nephrotic syndrome (MCNS) frequently have suppressed in vivo and in vitro immune responsiveness of uncertain etiology. Because increased suppressor cell activity has been associated with this disease, urines from MCNS patients were screened for activity of the lymphokine soluble immune response suppressor (SIRS), a product of concanavalin A- or interferon-activated suppressor T cells. Urines from untreated MCNS patients suppressed polyclonal plaque-forming cell responses of cultured splenocytes. This suppressive activity was identified as human SIRS by the following functional and physical criteria: molecular weight estimated by gel filtration; kinetics of suppression; inhibition of suppression by catalase, levamisole, and 2-mercaptoethanol; abrogation of activity by acid or protease treatment; elution pattern on high performance liquid chromatography; and cross-reactivity with monoclonal antimurine SIRS antibodies. Suppressive activity disappeared from urine after initiation of treatment but before remission of symptoms. Urines were tested from 11 patients with MCNS, all of whom excreted SIRS. In addition, two nephrotic patients with acute glomerulonephritis and three nephrotic patients with membranoproliferative disease excreted SIRS, but other nephrotics and all nonnephrotic patients did not. These results indicate that excretion of SIRS occurs in certain cases of nephrotic syndrome and that the presence of SIRS in the urine is not accounted for solely by the presence of proteinuria or nephrosis. Serum from four nephrotic patients also contained SIRS, whereas neither serum nor urine from six normal subjects contained SIRS activity. The systemic presence of SIRS in these four patients, and the identification of SIRS in urines from a larger group of patients, suggest a possible role for SIRS in the suppressed immune responses often found in nephrotic syndrome.
机译:最小变化肾病综合征(MCNS)的患者经常抑制不确定病因的体内和体外免疫反应。由于抑制细胞活性的增加与该疾病有关,因此对来自MCNS患者的尿液进行了淋巴因子可溶性免疫应答抑制剂(SIRS)(伴刀豆球蛋白A或干扰素激活的抑制T细胞的产物)的活性筛选。来自未经治疗的MCNS患者的尿液抑制了培养的脾细胞的多克隆菌斑形成细胞反应。通过以下功能和物理标准将该抑制活性鉴定为人SIRS:通过凝胶过滤估算的分子量;抑制动力学;过氧化氢酶,左旋咪唑和2-巯基乙醇的抑制作用;通过酸或蛋白酶处理消除活性;高效液相色谱的洗脱模式;和与单克隆抗鼠SIRS抗体的交叉反应。开始治疗后但症状缓解之前,尿中的抑制活性消失了。对11名MCNS患者的尿液进行了检测,所有患者均排泄了SIRS。此外,有2例急性肾小球肾炎的肾病患者和3例膜肺增生性疾病的肾病患者排泄了SIRS,但其他肾病患者和所有非肾病患者均未排泄。这些结果表明,在某些肾病综合征病例中会发生SIRS的排泄,而尿液中SIRS的存在并非仅由蛋白尿或肾病的存在引起。来自四名肾病患者的血清也含有SIRS,而来自六名正常受试者的血清和尿液均不具有SIRS活性。在这四位患者中,SIRS的全身性存在,以及从更多患者的尿液中识别出SIRS,提示SIRS在肾病综合征中常见的免疫反应抑制中可能发挥作用。

著录项

  • 作者

    Schnaper, H W; Aune, T M;

  • 作者单位
  • 年度 1985
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号